Wikio - Human Genome Sciences

Human Genome Sciences Reports Positive Long-Term Data For LymphoStat-B In Patients With Active Systemic Lupus Erythematosus (Medical News Today)

Fri, 13 Jun 2008 10:00:00 GMT

Human Genome Sciences, Inc.

Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus (PR News Wire )

Thu, 12 Jun 2008 11:00:00 GMT

... antagonists can reduce autoantibody levels and help control autoimmune disease activity. About Human Genome Sciences The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases....

Source : PR News Wire (subscribe)

Explore : Diseases, Health Industries, Lupus

Research and Markets: The Analysis of Human Genome Sciences Inc. Provides a Complete and Comprehensive Analysis of the Company (Business Wire)

Wed, 11 Jun 2008 11:00:00 GMT

The publisher presents Analysis of Human Genome Sciences Inc. - a complete and comprehensive analysis of Human Genome Sciences, includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.

Source : Business Wire (subscribe)

Explore : Dublin, Health Industries, Ireland

Human Genome Sciences Initiates Phase I Study in Advanced Solid Tumors (Red Orbit )

Mon, 02 Jun 2008 14:22:20 GMT

Human Genome Sciences has initiated dosing in a Phase I clinical trial to evaluate the safety and tolerability of its IAP inhibitor, HGS1029, as monotherapy in patients with advanced solid tumors.

Source : Red Orbit (subscribe)

Explore : Health, I.A.P., Record Labels

Lupus Medication Being Tested As Treatment For Multiple Sclerosis (VitaBeat)

Thu, 29 May 2008 16:05:01 GMT

A Maryland pharmaceutical firm is testing a lupus drug, LymphoStat-B, to treat multiple sclerosis. The medication stops a protein found in high levels in MS lesions, which contribute to the production of cells that go against the body and instead attack healthy tissue. Human Genome Sciences has partnered with GlaxosmithKline in testing LymphoStat-B to find a cure for MS, one of four autoimmune...

Source : VitaBeat (subscribe)

Explore : Drug Manufacturers, Lupus, Maryland

Human Genome Sciences shares rise on late - stage drugs progress, new trial initiation (Inbox Robot: Swiss Reinsurance News)

Wed, 28 May 2008 15:32:00 GMT

Late-stage data for another of the company's drug candidates, Albuferon, for chronic hepatitis C, will be available in the spring of 2009 in

Source : Inbox Robot: Swiss Reinsurance News (subscribe)

Explore : Drug Manufacturers

Human Genome Sciences reports progress with late-stage products (The Washington Business Journal )

Wed, 28 May 2008 13:02:12 GMT

Human Genome Sciences Inc. is reporting significant progress for three late-stage products. (HGSI)

Source : The Washington Business Journal (subscribe)

Explore : Business

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives (PR News Wire )

Wed, 28 May 2008 11:00:00 GMT

- Albuferon(R) for hepatitis C and LymphoStat-B(R) for lupus on track for potential launch in 2010 - - ABthrax(TM) for inhalation anthrax on track to begin delivery fall 2008 - - Pipeline strengthened with investments in oncology portfolio and new targets initiative - - GSK to advance darapladib to Phase 3 for atherosclerosis - ROCKVILLE, Md., May 28 /PRNewswire-FirstCall/ -- Human Genome...

Source : PR News Wire (subscribe)

Human Genome Sciences Invites Investors to Listen to Webcast of Presentations at Analyst & Investor Meeting (PR News Wire )

Wed, 21 May 2008 12:00:00 GMT

ROCKVILLE, Md., May 21 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: ) today announced that its presentations at its Analyst & Investor meeting will be webcast and may be accessed at . (Logo: ) Human Genome Sciences' senior management will provide an overview of the Company on Wednesday, May 28, 2008, beginning at 12 Noon Eastern Time. Investors interested in listening...
Source : PR News Wire (subscribe)
Explore : Drug Manufacturers, Health Industries

Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference (PR News Wire )

Fri, 16 May 2008 12:00:00 GMT

ROCKVILLE, Md., May 16 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: ) announced today that its presentation at the 2008 Citi Investment Research Global Healthcare Conference will be webcast and may be accessed at (Logo: ) A member of Human Genome Sciences' senior management team will present a corporate overview on Wednesday, May 21, 2008 at 3:00 pm Eastern Time. ...
Source : PR News Wire (subscribe)
Explore : Drug Manufacturers, Health Industries

Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise (PR News Wire )

Thu, 15 May 2008 11:00:00 GMT

ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: ) today announced that Kevin P. McRaith has joined the Company as Vice President, Hepatology Franchise. Mr. McRaith, formerly Vice President, Sales & Marketing - Hematology, Genentech Corporation, will report to Barry A. Labinger, Executive Vice President and Chief Commercial Officer. (Logo: ) "Kevin McRaith...
Source : PR News Wire (subscribe)
Explore : Drug Manufacturers, Health Industries

Human Genome Sciences Appoints John L. Lamattina, Ph.D., To Its Board of Directors (Red Orbit )

Thu, 08 May 2008 14:01:13 GMT

ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced that John L. LaMattina, Ph.D., who retired in late 2007 as President of Pfizer Global Research and Development, has been appointed to the HGS Board of Directors.
Source : Red Orbit (subscribe)
Explore : Drug Manufacturers, Health, Pfizer Inc.

Health Winners & Losers: Obagi (The Street)

twocents@thestreet.com (Elizabeth Trotta) — Tue, 06 May 2008 20:12:00 GMT

Obagi Medical Products and Human Genome Sciences both fall on earnings misses.
Source : The Street (subscribe)
Explore : Finance, Medical Products and Supplies

Human Genome Sciences Inc. Q1 2008 Earnings Call Transcript (Seeking Alpha)

Tue, 06 May 2008 01:18:09 GMT

Human Genome Sciences Inc. (HGSI) Q1 2008 Earnings Call Complete Story »
Source : Seeking Alpha (subscribe)
Explore : China

Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments (Red Orbit )

Mon, 05 May 2008 23:00:51 GMT

ROCKVILLE, Md., May 5 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced financial results and key developments for the quarter ended March 31, 2008.
Source : Red Orbit (subscribe)
Explore : Health

Human Genome Sciences cuts losses, advances clinical studies (The Washington Business Journal )

Mon, 05 May 2008 21:04:30 GMT

Human Genome Sciences Inc., which is developing drugs for lupus, hepatitis and liver cancer, reported a smaller loss for its latest quarter as it collects payments from its drug development partners. (HGSI)
Source : The Washington Business Journal (subscribe)
Explore : Business, Cancers, Liver Cancer, Lupus

Human Genome's stock down, not out (The Washington Times)

Tue, 29 Apr 2008 04:33:35 GMT

Human Genome Sciences shares are down about 28 percent in the past six months, but investors and...
Source : The Washington Times (subscribe)
Explore : Business

Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2008 Financial Results (PR News Wire )

Mon, 28 Apr 2008 20:05:00 GMT

... and great medicine to bring innovative drugs to patients with unmet medical needs. HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended....
Source : PR News Wire (subscribe)
Explore : Biotechnologies, Drug Manufacturers

Human Genome Sciences Completes Enrollment In First Of Two Phase 3 Lymphostat-B(R) Trials (Medical News Today)

Wed, 23 Apr 2008 07:00:00 GMT

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has completed enrollment and initial dosing in BLISS-52, one of two pivotal Phase 3 clinical trials of LymphoStat-B(R) (belimumab) in patients with active systemic lupus erythematosus (SLE).
Source : Medical News Today (subscribe)
Explore : Health, Lupus, NASDAQ

Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials (Life Science World)

Tue, 22 Apr 2008 15:09:00 GMT

[NEWS] - Completion of enrollment in second Phase 3 trial expected by end of summer - - First Phase 3 data now expected by mid-2009, with all Phase 3 data expected in fall 2009 - ROCKVILLE, Md., April 22 /PRNewswire-FirstCall/ — Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has completed enrollment and initial dosing in BLISS-52, one of two pivotal Phase 3 clinical trials...
Source : Life Science World (subscribe)
Explore : Biotechnologies, NASDAQ